Retatrutide vs. Wegovy: What the Data Actually Shows

The Temptation of Cross-Trial Comparisons

When retatrutide Phase 2 data showed up to 24.2% mean body weight loss at 48 weeks, the immediate question from clinicians and patients alike was: how does this compare to semaglutide 2.4 mg (Wegovy)? The answer requires careful interpretation, because these compounds were studied in different trials, with different patient populations, at different times.

Cross-trial comparisons — sometimes called naive indirect comparisons — are inherently limited. Differences in baseline BMI, demographics, comorbidity profiles, diet and exercise counseling intensity, and even placebo response rates can all influence outcomes. The only definitive way to compare two therapies is a head-to-head randomized controlled trial, which has not been conducted for retatrutide versus semaglutide 2.4 mg.

The Numbers at a Glance

In the STEP 1 trial, semaglutide 2.4 mg produced a mean body weight reduction of approximately 14.9% at 68 weeks in adults with obesity or overweight (BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity) without diabetes.

In the Phase 2 trial of retatrutide, the highest dose group (12 mg) achieved a mean weight loss of 24.2% at 48 weeks in a similar population of adults with obesity, at a shorter treatment duration with weight loss still trending downward.

Update — TRIUMPH-4 Phase 3 data (December 2025): We now have duration-matched data. TRIUMPH-4 enrolled 445 participants with obesity and knee osteoarthritis over 68 weeks — the same duration as STEP 1. The 12 mg group achieved 28.7% mean weight loss and the 9 mg group achieved 26.4%, compared to 2.1% on placebo. This eliminates the previous duration mismatch caveat and provides a more direct comparison: at the same 68-week timepoint, retatrutide at 12 mg produced roughly twice the weight loss of semaglutide 2.4 mg (28.7% vs. 14.9%).

These headline figures show a substantial difference in magnitude, though important contextual factors still deserve attention.

Mechanism: Triple vs. Single Agonist

Semaglutide is a selective GLP-1 receptor agonist. It reduces appetite, slows gastric emptying, and acts on central nervous system pathways involved in satiety.

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure through effects on hepatic metabolism and thermogenesis, while GIP receptor agonism may contribute to enhanced insulin sensitivity and potentially synergistic effects on appetite regulation.

This mechanistic difference is not trivial. Glucagon receptor activation in the context of obesity pharmacotherapy is a relatively novel approach, and its incremental contribution to weight loss beyond GLP-1 and GIP agonism is an active area of investigation.

Population and Trial Design Differences

Several differences between the STEP program and the retatrutide Phase 2 trial complicate direct comparison:

• Trial duration: The duration mismatch that previously complicated comparison has been partially resolved. TRIUMPH-4 ran for 68 weeks, matching STEP 1. However, TRIUMPH-4 enrolled a specific population (obesity with knee osteoarthritis), not the general obesity population studied in STEP 1.
• Baseline characteristics: Mean baseline BMI and body weight differed between trials, which can influence the percentage of weight lost. TRIUMPH-4 participants had knee OA as a required comorbidity, which may affect baseline characteristics and response.
• Sample size: STEP 1 enrolled over 1,900 participants. TRIUMPH-4 enrolled 445 participants. The upcoming TRIUMPH-1 trial (general obesity population) will provide a more directly comparable dataset.
• Lifestyle intervention: Both trials included lifestyle counseling, but the intensity and standardization of these interventions can vary.

Tolerability Considerations

Both agents share GLP-1 receptor agonism, so gastrointestinal side effects are common to both. TRIUMPH-4 Phase 3 data showed nausea (43.2%), diarrhea (33.1%), and vomiting (20.9%) at the 12 mg dose, with discontinuation rates of 18.2% at 12 mg versus 4.0% on placebo. A notable difference is dysesthesia (abnormal skin sensation), which occurred in 20.9% of the retatrutide 12 mg group — a finding not associated with semaglutide. This may be related to the glucagon receptor component and represents a meaningful tolerability distinction. Definitive tolerability comparisons still require head-to-head data.

What We Still Need

With TRIUMPH-4 providing the first Phase 3 data at 68 weeks, the efficacy comparison has become more concrete: retatrutide’s weight loss advantage over semaglutide 2.4 mg appears substantial and is now supported by Phase 3 evidence. Six additional TRIUMPH readouts are expected in 2026, including the core obesity trial (TRIUMPH-1) that will provide the most directly comparable population to STEP 1.

For clinicians and patients, the key takeaway is that retatrutide’s Phase 3 data confirm a meaningful efficacy advantage, but the evidence base for semaglutide 2.4 mg remains substantially more mature, with years of post-marketing data and cardiovascular outcomes evidence (SELECT trial). Treatment decisions should ultimately be guided by individual patient characteristics, tolerability — including retatrutide’s distinct dysesthesia signal — and the full body of evidence available at the time of prescribing.